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Germline variants within the transcription factor RUNX1 are associated with familial 
platelet disorder (FPD) and acute leukemia in over 40% of carriers. At present, the 
somatic events triggering leukemic transformation appear heterogeneous and profiles 
of leukemia initiation across family members are poorly defined. We report a 
new RUNX1 family where 3 sisters harboring a germline nonsense RUNX1 variant, 
c.601C>T (p.(Arg201*)), developed AML at 5 years of age. Whole exome sequencing of 
tumor samples revealed all 3 siblings independently acquired variants within the JAK-
STAT pathway, specifically targeting JAK2 and SH2B3 (a negative regulator of JAK2), 
while also sharing the 46/1 haplotype linked with sporadic JAK2-positive 
myeloproliferative neoplasms (MPNs). In-depth chromosomal characterization of 
tumors revealed acquired copy number gains and uniparental disomy 
amplifying RUNX1, JAK2 and SH2B3 variants, highlighting the significance of co-
operation between these disrupted pathways. One sibling, presenting with MDS at 14 
years, had no evidence of clonal or subclonal JAK2 or SH2B3 variants, suggesting the 
latter were specifically associated with leukemic transformation in her 
sisters. Collectively, the clinical and molecular homogeneity across these 3 young 
siblings provides the first notable example of convergent AML evolution in a RUNX1 
pedigree, with the recurrent acquisition of JAK-STAT pathway variants giving rise 
to high-risk AML, characterized by chemotherapy resistance and relapse. 
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Acquired RUNX1 variants occur in approximately 10% of sporadic AML cases and the 
clinico-pathologic associations within this subgroup of disease have been 
comprehensively defined (1). Inherited or germline RUNX1 variants are 
comparatively rare and typically cluster in the highly-conserved runt homology 
domain (RHD), predisposing to familial platelet disorder (FPD) and myelodysplasia 
(MDS) or acute leukemia (2).  Leukemic transformation occurs in over 40% of variant 
carriers, coinciding with a heterogeneous profile of somatic genetic lesions, 
although aberrations of the second RUNX1 allele or amplification of the germline 
variant are frequent (3-4). Notably, CDC25C variants were reported as a recurrent 
event in a Japanese RUNX1 mutated cohort (5), however these results were not 
replicated in US and European studies (3, 6, 7), suggesting ethnicity may influence 
somatic variant acquisition. Exploring this notion further, we considered whether 
family members may develop similar patterns of disease, due to their common 
genetic background.  Using comprehensive clinical and genetic profiling of multiple 
siblings with MDS/AML, we report striking phenotypic and molecular convergence 
of AML within a new Hungarian RUNX1-mutated family.  
  
DESIGN AND METHODS 
We used the SureSelect All Exon V5 kit (Agilent) to perform whole exome 
sequencing (WES) on bone marrow (BM) tumor DNA from siblings (II.1-II.4) and 




peripheral blood (PB) DNA from both healthy parents (I.1 and I.2), the latter 
providing a germline reference. Enriched exome libraries were sequenced to an 
average depth of 96x (Table S1) using the HiSeq 2000 (Illumina) with additional 
analysis described in Supplementary Data.  
  
An established pipeline incorporating MuTect (single nucleotide variants, SNVs) and 
GATK (indels) was employed for variant calling in tumor samples.  Analysis of 
chromosomal loss of heterozygosity (LOH), including copy number aberrations 
(CNAs) and acquired uniparental disomy (aUPD) is detailed in the Supplementary 
Data.  Sequence variants and CNAs were verified using Sanger sequencing and 
multiplex ligation-dependent probe amplification (MRC Holland, SALSA X060-X2), 
respectively. The WES data have been deposited in the European Genome-Phenome 
Archive under the accession number EGAS00001001862. Deep sequencing of JAK2 
exon 14 and all coding exons of SH2B3 was performed using the AmpliSeq approach 
on an Ion Torrent (Life Technologies) instrument. The reference sequences used for 
variant annotations are listed in the Supplementary Data. 
 
RESULTS  
A nonsense RUNX1 variant, c.601C>T (p.(Arg201*)), was detected in all four siblings 
and their mother, (Figure 1A, B; Table S2).  The first affected family members were 
dizygotic twins (II.1 and II.2) who presented in 2002 at 5 years of age, within a 




period of 14 days.  They both had hepatosplenomegaly and monocytosis, with BM 
morphology revealing acute myelomonocytic leukemia (FAB AML M4).  After 6 
years, sibling II.4 presented with thrombocytopenia aged 1 year, followed by acute 
myelomonocytic leukemia (FAB AML M4) at 5 years of age.  In contrast, sibling II.3 
developed mild anemia and thrombocytopenia and was diagnosed with multilineage 
dysplasia (RCMD) at 14 years. Their mother (I.1, 44 years) remains an asymptomatic 
carrier, with normal peripheral blood indices and no history of mucosal bleeding or 
bruising to suggest platelet dysfunction (Figure 1C).  
Cytogenetic analysis of tumor samples revealed gain of 21q (46,XX,der(21).ish 
amp(RUNX1)[15]/46,XX[5]) in II.1, amplifying the germline RUNX1 variant (c.601C>T 
(p.(Arg201*)) WES variant allele frequency [VAF] 67%); additional events included 
monosomy 7 and deletion of 9q ((45,XX,-
7[2]/45,XX,idem,del(9)(q21q31)[17]/46,XX[1]) in II.2, while II.3 and II.4 had a normal 
karyotype.  WES identified a median of 11 somatic non-synonymous variants (range 
10-11), with 97% (n=39) comprising SNVs, Table S3. Targeted analysis of WES data 
from the mother and father confirmed the absence of variants in established pre-
leukemic loci, confirming that additional germline lesions with known pathogenic 
relevance were not harbored by the siblings. 
 
 All 3 siblings with AML (II.2, II.3 and II.4) acquired variants upregulating JAK2 
signalling, as shown in Figure 1C.  In II.2 and II.4, JAK2 c.1849G>T (p.(Val617Phe)) 
was detected, with the variant dosage amplified by 9p aUPD in II.2 (p.(Val617Phe) 




VAF 68%, Figure 2A(i)).  Sibling II.1 acquired a unique variant (c.1175G>A 
(p.(Arg392Gln))) in SH2B3, with 12q aUPD increasing its allelic burden to 67% (Figure 
2A(ii)). SH2B3 (also known as LNK) is a member of the SH2B family of adaptor 
proteins and negatively regulates JAK2 by interacting with the phosphorylated JAK2 
tyrosine residue 813 (p.Tyr813) via a conserved SH2 domain, regulating both WT 
and mutant JAK2 activity (8).  By analyzing the structure of murine Sh2b, we 
identified that SH2B3 p.Arg392 corresponds to Sh2b p.Arg555 (9), situated in the 
midst of a precisely conserved region spanning 15 amino acids and forming a salt 
bridge with the phosphopeptide binding pocket targeted by phosphorylated JAK2.  
SH2B3 c.1175G>A (p.(Arg392Gln)) is a unique variant, predicted to be damaging 
using MutationTaster (p=1.0000 4d.p., http://www.mutationtaster.org) and absent 
from both ExAC (http://exac.broadinstitute.org) and Thousand Genome databases 
(http://www.internationalgenome.org/data/).  We hypothesise that p.(Arg392Gln) 
may therefore disrupt salt-bridging with the phosphopeptide binding pocket in 
SH2B3, consequently reducing JAK2 inhibition, as previously described with 
missense variants in this domain (10).  
 
Additional somatic variants identified across the siblings included the anaphase 
promoting complex component, CDC27, in II.2 (c.1901T>C (p.(Ile634Thr)), VAF 
16.7%) and II.3 (c.1477A>G (p.(Ile493Val)), VAF 7.5%); RBBP8 (DNA double strand 
break repair, c.959A>G (p.(Glu320Gly)), VAF 32.3%) and CHD4 (nucleosome 
remodelling and histone deacetylase complex, c.3530G>A (p.(Arg1177His)), VAF 




5.6%) in II.2 and U2AF2 (spliceosome component, c.439C>G (p.(Gln147Glu)), VAF 
41.2%) in sibling II.4. These molecular lesions are infrequently observed in sporadic 
MDS/AML, mirroring observations within other RUNX1 pedigrees where only 1-2 
recurrently mutated driver events are detected in tumors (3, 6,7,11).  
  
Having established the spectrum of variants across the siblings, we next sought to 
derive the chronological sequence of chromosomal and genetic aberrations by 
calculating their respective cancer cell fractions (CCFs) based on the ‘‘Battenberg’’ 
algorithm (12) (Figures 2B-C and Supplementary Data).  In II.1, SH2B3 c.1175G>A 
(p.(Arg392Gln)) and 12q aUPD preceded gain of 21q; while in II.2, monosomy 7, 
JAK2 c.1849G>T (p.(Val617Phe)) and 12q aUPD were followed by 9q deletion, Figure 
2D.  This pattern of disease evolution revealed the selective and sequential 
amplification of RUNX1, JAK2 and SH2B3 variants, affirming their key roles as 
leukemic driver lesions.    
  
The rarity of JAK2 and SH2B3 variants in sporadic AML cases (13), suggested these 
siblings may share an inherited genotype predisposing to the specific acquisition of 
JAK-STAT pathway variants.  The JAK2 46/1 haplotype is associated with an 
increased population risk of developing JAK2 p.(Val617Phe) positive MPNs and 
sequencing of rs12340895 (in linkage disequilibrium [LD] with this haplotype) 
revealed heterozygosity in all 4 children (GC).  Notably, 9p aUPD in II.2 amplified 
both V617F and rs12340895 variants, showing that p.(Val617Phe) was acquired on 




the 46/1 allele, as in sporadic neoplasms (14-16).  The mother was homozygous for 
the 46/1 haplotype (GG) and the father was homozygous for the non-46/1 allele 
(CC) (Figure 3).  Subclonal JAK2 and SH2B3 variants, were excluded in sibling II.3 and 
maternal DNA (I.1) by deep sequencing to a depth of 10,000x, suggesting that these 
lesions were specifically acquired upon leukemic transformation, potentially 
influenced by additional, yet unknown, genetic variants. 
 
All 3 siblings with AML and JAK2 upregulation demonstrated an aggressive disease 
course, characterized by relapse and resistance to chemotherapy.  Following 
combination chemotherapy, II.1 achieved complete remission (CR) but died one 
year later with AML relapse. II.2 failed to achieve CR and succumbed to 
chemotherapy-refractory disease after 8 months.  Sibling II.4, received induction 
chemotherapy with idarubicin, cytarabine and etoposide, and underwent unrelated 
double cord-blood stem cell transplantation (HSCT) following a delay in 
hematopoietic reconstitution.  AML recurred after 17 months requiring a second 
volunteer unrelated donor-HSCT and she continues in remission with full donor 
chimerism 30 months post-transplant.    
 
Discussion 
In this study, we report a novel RUNX1 pedigree with recurrence of somatic JAK-
STAT pathway variants in 3 siblings with aggressive myelomonocytic AML. Our data 
suggest that inherited genetic traits may govern leukemic transformation and 




disease behavior by influencing somatic variant acquisition and molecular co-
operation. Concurrent disruption of JAK2 and RUNX1 has been reported in sporadic 
AML, where JAK2 variants occur in 5-8% of core binding factor leukemia with the  
t(8;21)(q22;q22) RUNX1-RUNX1T1 translocation (17, 18) and in a study of 200 AML 
cases, solitary SH2B3 and JAK2 c.1849G>T (p.(Val617Phe)) variants both coincided 
with RUNX1 variants (13). Conversely, RUNX1 variants have also been reported 
during leukemic transformation of JAK2-positive MPNs (19, 20). The lack of 
recurrent JAK-STAT variants in a recent study of RUNX1-mutated AML (1) suggests 
that this co-operation is rare and likely to be governed by additional features, 
including haplotype. Clinically, all 3 siblings with somatic JAK-STAT pathway variants 
demonstrated an adverse disease profile, highlighting the importance of observing 
phenotypic patterns of disease across family members to improve investigation, 
management and counselling of these rare pedigrees. 
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TITLES AND LEGENDS TO FIGURES  
 
Figure 1. Profile of a novel RUNX1-mutated pedigree. (A) Novel RUNX1 pedigree 
showing affected individuals (black shading) and asymptomatic carriage of germline 
variant (grey shading).  (B) RUNX1 c.601C>T (p.(Arg201*)) variant identified in 4 
siblings and their mother, the corresponding WES VAFs are shown (C) Clinical 
timeline of the pedigree showing siblings II.1, II.2 and II.4 presenting with AML at 5 
years of age.  All 3 siblings with AML acquired variants upregulating JAK-STAT 
signalling, while sibling II.3 remains under expectant follow up with MDS. (RUNX1 
reference sequences: ENSG00000159216 / ENST00000300305. 
 
    
Figure 2. Detailed analysis of chromosomal LOH to decipher sequence of genetic 
lesions. (A) i) WES B-allele frequencies (BAFs) demonstrated 12q aUPD (hg19 
coordinates: chr12:102,468,734-133,810,703), causing homozygosity of the SH2B3 
c.1175G>A (p.(Arg392Gln)) variant in II.1.  In II.2, 9p aUPD (hg19 coordinates: 
chr9:154,795-16,277,713), led to homozygosity of JAK2 c.1849G>T (p.(Val617Phe)). 
9q loss was also detected in II.2, characterized by reduced LogR ratios (LRR). (B) i) 
Plot of LRR and BAF for variants within 12q (blue) and 21q (red) in II.1.  ii) Density 
plots showing the BAF of variants within regions of LOH, the peak density was used 
to calculate the CCF of each chromosomal lesion.  (C) i) Plot of LRR and BAF for 
variants on chromosome 7 (blue), 9p (red) and 9q (green) in II.2.  ii) Density plots 
showing the BAF of variants within the corresponding chromosomal regions, with 
the peak density used to calculate CCF.  (D) From the calculations in (B) and (C), the 
CCF for each LOH segment was calculated allowing the evolutionary sequence to be 
determined in II.1 and II.2.  In II.4, somatic LOH was not detected at AML diagnosis 
and variant CCFs were estimated using VAFs.  
 
Figure3. Identification of JAK2 46/1 haplotype in mother and children. Sequencing 
of JAK2 rs12340895 in LD with the 46/1 haplotype, revealed the mother (I.1) was 
homozygous (GG) for the 46/1 haplotype and the father was homozygous for the 
non-46/1 allele (CC).  All four children were heterozygous for the 46/1 haplotype 
(GC), with II.2 demonstrating prominence of the 46/1 allele due to 9p aUPD, 
confirming JAK2 c.1849G>T (p.(Val617Phe)) (also subject to dosage amplification) was 
acquired on the 46/1 allele. 
  
 



